A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas

Cancer

Volumn 118, Issue 14, 2012, Pages 3538-3548

  Sinha, Rajni ^a   Kaufman, Jonathan L ^a   Khoury Jr , Hanna Jean ^a   King, Nassoma ^a   Shenoy, Pareen J ^a   Lewis, Carol ^a   Bumpers, Kevin ^a   Hutchison Rzepka, Amanda ^a   Tighiouart, Mourad ^a   Heffner, Leonard T ^a   Lechowicz, Mary Jo ^a   Lonial, Sagar ^a   Flowers, Christopher R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bortezomib; cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); follicular lymphoma; maximum tolerated dose; non Hodgkin lymphoma; phase 1 clinical trials; rituximab; toxicity

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPEPSIA; FATIGUE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LYMPHOCYTOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEURAL CONDUCTION; PREDNISONE; PYRAZINES; VINCRISTINE;

EID: 84863317276     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26660     Document Type: Article

References (43)

1. Czuczman MS,. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol. 1999; 26 (5 suppl 14): 88-96. (Pubitemid 29523416)
2. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI,. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005; 46: 1569-1573. (Pubitemid 41700989)
3. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 3725-3732. (Pubitemid 41742196)
4. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105: 1417-1423. (Pubitemid 40223656)
5. Orina JN, Moore SG, Lechowicz MJ, Flowers CR,. Determining the benefits of chemotherapy for achieving complete response in patients with untreated advanced stage follicular lymphoma: a systematic review and meta-analysis [abstract]. Blood (ASH Annual Meeting Abstracts). 2005; 106. Abstract 290.
6. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP,. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005; 23: 8447-8452.
7. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS,. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107: 265-276. (Pubitemid 43053551)
8. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009; 27: 1202-1208.
9. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ,. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004; 22: 4711-4716.
10. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol. 2006; 24: 1582-1589. (Pubitemid 46638782)
11. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol. 2001; 12: 109-114. (Pubitemid 32162456)
12. Bachy E, Brice P, Delarue R, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2010; 28: 822-829.
13. Jazirehi AR, Vega MI, Bonavida B,. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007; 67: 1270-1281.
14. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74: 597-608. (Pubitemid 23259741)
15. O'Connor OA,. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma. 2005; 6: 191-199.
16. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009; 27: 5023-5030.
17. Furman RR, Martin P, Ruan J, et al. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010; 116: 5432-5439.
18. Ribrag V, Gisselbrecht C, Haioun C, et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer. 2009; 115: 4540-4546.
19. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2010; 29: 690-697.
20. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol. 1998; 16: 2332-2338. (Pubitemid 28309024)
21. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma International Prognostic Index. Blood. 2004; 104: 1258-1265. (Pubitemid 39166497)
22. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008; 26: 4579-4586.
23. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003; 13: 741-748. (Pubitemid 38235217)
24. Tavee J, Zhou L,. Small fiber neuropathy: a burning problem. Cleve Clin J Med. 2009; 76: 297-305.
25. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586. (Pubitemid 350002966)
26. Babb J, Rogatko A, Zacks S,. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998; 17: 1103-1120. (Pubitemid 28221028)
27. Babb JS, Rogatko A,. Bayesian Methods for Cancer Phase I Clinical Trials. New York: Marcel Dekker; 2004.
28. Tighiouart M, Rogatko A, Babb JS,. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med. 2005; 24: 2183-2196. (Pubitemid 40960215)
29. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 3121-3127. (Pubitemid 46638950)
30. Rummel MJ, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas-final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 856.
31. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011; 117: 2807-2812.
32. National Cancer Institute. Bendamustine hydrochloride and rituximab with or without bortezomib followed by rituximab with or without lenalidomide in treating patients with high-risk stage II, stage III, or stage IV follicular lymphoma. Bethesda, MD: National Cancer Institute; 2010. Available at:. Accessed May 25, 2011.
33. Leonard JP, Furman RR, Cheung YK, et al. Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results [abstract]. Blood (ASH Annual Meeting Abstracts). 2005; 106. Abstract 491.
34. Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol. 2010; 151: 47-53.
35. Kahl BS, Peterson C, Blank J, et al. A feasibility study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma [abstract]. J Clin Oncol. 2007; 25 (18S June 20 suppl). Abstract 8062.
36. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG 1496 study. J Clin Oncol. 2009; 27: 1607-1614.
37. Martinelli G, Hsu Schmitz S-F, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at 2 different schedules in Trial SAKK 35/98. J Clin Oncol. 2010; 28: 4480-4484.
38. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2010; 377: 42-51.
39. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998; 9: 995-1001. (Pubitemid 28496709)
40. Ghielmini M, Schmitz S-FH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004; 103: 4416-4423. (Pubitemid 38745964)
41. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW,. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005; 23: 1096-1102. (Pubitemid 46202264)
42. Mihelic R, Kaufman J, Lonial S, Flowers C,. Maintenance therapy in lymphoma. Clin Lymphoma Myeloma. 2007; 7: 507-513. (Pubitemid 350054863)
43. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA,. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Res. Network. J Clin Oncol. 2005; 23: 1088-1095. (Pubitemid 46202263)